hepatitis a vaccine, inactivated (vaqta) Report issue

Vaccine Approved FDA
AACT DrugBank MeSH

Active Ingredient History

NOW
  • Now
Hepatitis A vaccine is a vaccine that prevents hepatitis A. It is effective in around 95% of cases and lasts for at least twenty years and possibly a person's entire life. If given, two doses are recommended beginning after the age of one. It is given by injection into a muscle. The first hepatitis A vaccine was approved in Europe in 1991, and the United States in 1995. It is on the World Health Organization's List of Essential Medicines.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

avaxim | havrix | healive | hepatitis a-b vaccine | hepatitis a (control) | hepatitis a inactivated virus vaccine | hepatitis a vaccine | hepatitis a vaccine, inactivated | hepatitis a vaccine, inactivated, nuclease purified | hepatitis a virus vaccine | hepatits a vaccine | inactivated hav vaccine, lu8 strain | inactivated hav vaccine, tz84 strain | inactivated hepatitis a vaccine | inactivated hep a vaccine | twinrix | vaqta

Organizations (82)

Research & Development (82)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (50)

Approved Indications (1)


 

Hepatitis A Vaccines (approved 1995)

Experimental Indications - Clinical Trial Phases 1-4 (50)


 

Breast Neoplasms (Phase 1)

Chickenpox (Phase 4)

Colorectal Neoplasms (Phase 1)

Coronavirus (Phase 2)

COVID-19 (Phase 4)

Dengue (Phase 3)

Dengue Virus (Phase 2)

Diphtheria (Phase 4)

Encephalitis (Phase 4)

Encephalitis, Japanese (Phase 3)

Haemophilus influenzae type b (Phase 3)

Healthy Volunteers (Phase 4)

Hepatitis A (Phase 4)

Hepatitis A Vaccines (Phase 3)

Hepatitis A virus (Phase 4)

Hepatitis B (Phase 4)

Herpes Simplex (Phase 3)

HIV (Phase 4)

HIV Infections (Phase 4)

Immune System Diseases (Phase 4)

Influenza, Human (Phase 4)

Lung Diseases (Phase 1)

Malaria (Phase 2)

Measles (Phase 4)

Measles-Mumps-Rubella Vaccine (Phase 3)

Meningitis, Meningococcal (Phase 3)

Meningococcal Infections (Phase 4)

Meningococcal Vaccines (Phase 3)

Mumps (Phase 4)

Neisseria meningitidis (Phase 3)

Papillomavirus Infections (Phase 3)

Paratyphoid Fever (Phase 4)

Pertussis Vaccine (Phase 4)

Pneumococcal Infections (Phase 3)

Pneumococcal Vaccines (Phase 3)

Pneumonia, Pneumococcal (Phase 4)

Precancerous Conditions (Phase 3)

Rubella (Phase 4)

SARS-CoV-2 (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Severe Dengue (Phase 3)

Streptococcal Infections (Phase 3)

Streptococcus pneumoniae (Phase 3)

Tetanus (Phase 4)

Typhoid Fever (Phase 4)

Urinary Bladder Neoplasms (Phase 1)

Uterine Cervical Neoplasms (Phase 3)

Vaccination (Phase 4)

Vaccines (Phase 4)

Yellow Fever (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 110
  • # of Trial Organizations: 82

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue